A detailed history of Wells Fargo & Company transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Wells Fargo & Company holds 230 shares of MREO stock, worth $782. This represents 0.0% of its overall portfolio holdings.

Number of Shares
230
Previous 230 -0.0%
Holding current value
$782
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$1.15 - $1.67 $5,750 - $8,350
-5,000 Reduced 95.6%
230 $0
Q2 2023

Aug 15, 2023

BUY
$0.79 - $1.43 $3,950 - $7,151
5,001 Added 2183.84%
5,230 $6,000
Q1 2023

May 12, 2023

SELL
$0.71 - $1.22 $0 - $1
-1 Reduced 0.43%
229 $0
Q4 2022

Feb 13, 2023

SELL
$0.5 - $1.01 $250 - $505
-500 Reduced 68.49%
230 $0
Q3 2022

Nov 14, 2022

BUY
$0.82 - $1.73 $410 - $865
500 Added 217.39%
730 $0
Q4 2021

Feb 14, 2022

SELL
$1.51 - $2.59 $4,530 - $7,770
-3,000 Reduced 92.88%
230 $0
Q1 2021

May 13, 2021

BUY
$2.6 - $4.43 $7,800 - $13,290
3,000 Added 1304.35%
3,230 $11,000
Q3 2020

Nov 05, 2020

BUY
$2.55 - $3.29 $2 - $3
1 Added 0.44%
230 $1,000
Q1 2020

May 14, 2020

BUY
$0.8 - $3.21 $183 - $735
229 New
229 $0

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $425M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.